Peripheral blood stem cells for allogeneic transplantation: A review

Stem Cells

Volumn 19, Issue 2, 2001, Pages 108-117

  Cutler, Corey ^a   Antin, Joseph H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Allogeneic; Apheresis; Hematologic malignancies; Peripheral blood stem cell. CD34+; Transplantation

Indexed keywords

CD34 ANTIGEN; RECOMBINANT COLONY STIMULATING FACTOR;

ALLOTRANSPLANTATION; APHERESIS; BONE MARROW APLASIA; BONE MARROW CELL; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA; MORBIDITY; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHENOTYPE; RELAPSE; REVIEW; T LYMPHOCYTE;

EID: 0035099986     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.19-2-108     Document Type: Review

References (84)

1. Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukaemia in blast-cell transformation
2. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy
3. Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor
4. The biology and clinical uses of blood stem cells
5. + cell determination by flow cytometry
6. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis
7. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors
8. Effects of granulocyte-colony-stimulating factor on potential normal granulocyte donors
9. Collection of peripheral blood stem cells from normal donors 60 years of age or older
10. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): Occurrence in an allogeneic donor of peripheral blood stem cells
11. Administration of recombinant human granulocyte colony-stimulating factor to normal donors: Results of the Spanish National Donor Registry
12. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor
13. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs. blood stem cell transplantation
14. Blood stem cell procurement: Donor safety issues
15. Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: Leukacytapheresis and bone marrow harvest
16. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors
17. Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
18. Randomized trial of bone marrow versus Lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Fraņaise de Greffe de Moelle
19. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial
20. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
21. + cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies
22. + cell dose on engraftment in allogeneic peripheral blood stem cell transplantation
23. Allogeneic peripheral blood stem cell transplantation for haematological malignancies - An analysis of kinetics of engraftment and GVHD risk
24. + peripheral blood progenitor cell dose on hematopoietic recovery
25. + enrichment by density gradient separation
26. + selected cells from peripheral blood
27. The addition of allogeneic peripheral blood-derived progenitor cells to bone marrow for transplantation: Results of a randomised clinical trial
28. Bone marrow mobilized with granulocyte colony-stimulating factor in related allogeneic transplant recipients: A study of 29 patients
29. Long-term follow-up after allogeneic granulocyte colony-stimulating factor-primed bone marrow transplantation
30. Comparison of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells and G-CSF-stimulated bone marrow as a source of stem cells in HLA-matched sibling transplantation
31. Allogeneic blood stem cell transplantation in advanced hematologic cancers
32. Valuing clinical strategies early in development: A cost analysis of allogeneic peripheral blood stem cell transplantation
33. Cytokine dysregulation and acute graft-versus-host disease
34. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation
35. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease
36. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation
37. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells
38. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient
39. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies
40. A prospective, randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
41. Allogeneic transplantation with blood stem cells mobilized by rhG-CSF for hematological malignancies
42. Allogeneic bone marrow or peripheral blood cell transplants in adults with hematologic malignancies: A single-center experience
43. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
44. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: A retrospective comparison of short-term outcome with bone marrow transplantation
45. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
46. Allogeneic blood stem cells and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: Influence of stem cell source on outcome
47. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: A case controlled study
48. Chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation from matched related donors. A case-control study
49. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
50. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse
51. Incidence of acute and chronic graft-versus-host disease after allogeneic peripheral blood stem cell and bone marrow transplantation: A meta-analysis
52. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow
53. Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups
54. Autologous stem cell transplantation in chronic myelogenous leukemia: A retrospective analysis of the European Group for Bone Marrow Transplantation
55. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
56. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
57. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
58. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
59. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission
60. Autologous peripheral blood haematopoietic stem cell transplantation for chronic myelogenous leukaemia
61. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
62. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting
63. Donor lymphocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
64. Graft-versus-myeloma
65. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma
66. Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells
67. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
68. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation
69. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: Early transplantation is associated with improved outcome
70. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia
71. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: A long-term study of 71 patients
72. Allogeneic bone marrow transplantation for myelodysplastic syndrome: Outcomes analysis according to IPSS score
73. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
74. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
75. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
76. Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma
77. Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma
78. Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model
79. Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients
80. Donor buffy coat cell infusion after marrow transplantation for aplastic anemia
81. Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation
82. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
83. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
84. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma